These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
55. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395 [TBL] [Abstract][Full Text] [Related]
56. Plasmapheresis therapy in myasthenia gravis. Dau PC Muscle Nerve; 1980; 3(6):468-82. PubMed ID: 7453714 [TBL] [Abstract][Full Text] [Related]
57. Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids. Tannemaat MR; Verschuuren JJGM Neuromuscul Disord; 2020 Feb; 30(2):111-119. PubMed ID: 32007304 [TBL] [Abstract][Full Text] [Related]
58. Myasthenia and the neuromuscular junction. Gilhus NE Curr Opin Neurol; 2012 Oct; 25(5):523-9. PubMed ID: 22892950 [TBL] [Abstract][Full Text] [Related]
59. Treatment and clinical research in myasthenia gravis: how far have we come? Barohn RJ Ann N Y Acad Sci; 2008; 1132():225-32. PubMed ID: 18567872 [TBL] [Abstract][Full Text] [Related]
60. Problems in the optimal management of myasthenia gravis patients--a prospective clinical survey at Kalafong Hospital. Mafojane NA; Bill PL; Lotz BP S Afr Med J; 2002 Mar; 92(3):225-30. PubMed ID: 12040952 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]